The amount of current financial liabilities. [Refer: Financial liabilities]

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 7
-IssueDate 2022-03-24
-Paragraph 25
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_25&doctype=Standard
-URIDate 2022-03-24

+ Details

Name:	ifrs-full_CurrentFinancialLiabilities
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The amount of income associated with interest and other financing activities of the entity.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Name IAS
-Number 1
-IssueDate 2022-03-24
-Paragraph 85
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_85&doctype=Standard
-URIDate 2022-03-24

+ Details

Name:	ifrs-full_FinanceIncome
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The amount of assets that are: (a) cash; (b) an equity instrument of another entity; (c) a contractual right: (i) to receive cash or another financial asset from another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially favourable to the entity; or (d) a contract that will, or may be, settled in the entity’s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to receive a variable number of the entity’s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity’s own equity instruments. For this purpose the entity’s own equity instruments do not include puttable financial instruments classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity’s own equity instruments. [Refer: Financial instruments, class [member]; Financial liabilities]

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 7
-IssueDate 2022-03-24
-Paragraph 35H
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35H&doctype=Standard
-URIDate 2022-03-24

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 7
-IssueDate 2022-03-24
-Paragraph 35M
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35M&doctype=Standard
-URIDate 2022-03-24

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Name IFRS
-Number 7
-IssueDate 2022-03-24
-Paragraph 35N
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35N&doctype=Standard
-URIDate 2022-03-24

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 7
-IssueDate 2022-03-24
-Paragraph 35I
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35I&doctype=Standard
-URIDate 2022-03-24

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 7
-IssueDate 2022-03-24
-Paragraph 25
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_25&doctype=Standard
-URIDate 2022-03-24

+ Details

Name:	ifrs-full_FinancialAssets
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

The gross loss arising from exchange differences recognised in profit or loss, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: Foreign exchange gain (loss)]

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 21
-IssueDate 2022-03-24
-Paragraph 52
-Subparagraph a
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2022-en-r&anchor=para_52_a&doctype=Standard
-URIDate 2022-03-24

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2022-03-24
-Paragraph 35
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_35&doctype=Standard
-URIDate 2022-03-24

+ Details

Name:	ifrs-full_ForeignExchangeLoss
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The amount of expense arising from interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2022-03-24
-Paragraph 28
-Subparagraph e
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_28_e&doctype=Standard
-URIDate 2022-03-24

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2022-03-24
-Paragraph 23
-Subparagraph d
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_23_d&doctype=Standard
-URIDate 2022-03-24

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 12
-IssueDate 2022-03-24
-Paragraph B13
-Subparagraph f
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B13_f&doctype=Appendix&subtype=B
-URIDate 2022-03-24

+ Details

Name:	ifrs-full_InterestExpense
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The amount of non-current financial liabilities. [Refer: Financial liabilities]

+ References

+ Details

Name:	ifrs-full_NoncurrentFinancialLiabilities
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Additional Information [Line Items]

+ References

No definition available.

+ Details

Name:	mor_AdditionalInformationLineItems
Namespace Prefix:	mor_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Percentage of future development costs for clinical trials.

+ References

No definition available.

+ Details

Name:	mor_PercentageOfFutureDevelopmentCostsForClinicalTrials
Namespace Prefix:	mor_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Percentage of shares in development cost.

+ References

No definition available.

+ Details

Name:	mor_PercentageOfSharesInDevelopmentCost
Namespace Prefix:	mor_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Percentage on share of profit loss of associates and joint ventures.

+ References

No definition available.

+ Details

Name:	mor_PercentageOnShareOfProfitLossOfAssociatesAndJointVentures
Namespace Prefix:	mor_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Revenue recognition milestone method revenue recognized.

+ References

No definition available.

+ Details

Name:	mor_RevenueRecognitionMilestoneMethodRevenueRecognized
Namespace Prefix:	mor_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	mor_BalanceSheetLocationAxis=mor_FinancialAssetsFromCollaborationsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_CategoriesOfRelatedPartiesAxis=mor_IncyteMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_CategoriesOfRelatedPartiesAxis=mor_MorphosysMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Notes to the Balance Sheet - Summary of Financial Assets from Collaborations - Additional Information (Details) $ in Millions	12 Months Ended
	Dec. 31, 2022 EUR (€) Rate	Dec. 31, 2022 USD ($)	Dec. 31, 2021 EUR (€)	Dec. 31, 2020 EUR (€)	Dec. 31, 2022 USD ($) Rate
Additional Information [Line Items]
Revenue Recognition Milestone Method Revenue Recognized	€ 1,031,300,000
Percentage on share of profit loss of associates and joint ventures \| Rate	50.00%				50.00%
Financial assets			€ 1,085,053,000
Current financial liabilities	€ 145,295,000
Non-current financial liabilities	1,907,776,000
Finance Income	412,065,798		96,612,146	€ 92,047,221
Interest expense	2,752,000		€ 2,415,000	€ 1,021,000
Financial Assets from Collaborations [Member]
Additional Information [Line Items]
Finance Income	354,400,000
Foreign exchange loss	(37,400,000)
Interest expense	23,000,000
Incyte [member]
Additional Information [Line Items]
Financial assets	€ 0				$ 0.0
Percentage of shares in development cost \| Rate	55.00%				55.00%
Current financial liabilities	€ 2,500,000				$ 2.7
Non-current financial liabilities	€ 217,800,000				$ 232.3
Morphosys [member]
Additional Information [Line Items]
Percentage of shares in development cost \| Rate	45.00%				45.00%
Top of range [member]
Additional Information [Line Items]
Revenue Recognition Milestone Method Revenue Recognized \| $		$ 1,100.0
Top of range [member] \| Incyte [member]
Additional Information [Line Items]
Percentage of future development costs for clinical trials \| Rate	100.00%				100.00%